TY - JOUR
T1 - Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease
AU - Markopoulou, K.
AU - Dickson, D. W.
AU - McComb, R. D.
AU - Wszolek, Z. K.
AU - Katechalidou, L.
AU - Avery, L.
AU - Stansbury, M. S.
AU - Chase, B. A.
N1 - Funding Information:
Acknowledgments Supported by NIH grants P50-AG25711, P50-AG16574, P50-NS40256, P01-AG17216, P01-AG03949, R15-NS043162 and a seed grant to KM from the University of Nebraska Medical Center. The histological support of Virginia Phillips, Linda Rousseau and Monica Casey-Castanedes is greatly appreciated.
PY - 2008/7
Y1 - 2008/7
N2 - Individuals with familial Parkinson's disease (PD) due to a monogenic defect can show considerable clinical and neuropathological variability. To identify factors underlying this variability, histopathological analysis was performed in two clinically different A53T α-synuclein heterozygotes from Family H, a multigenerational α-synuclein A53T kindred. To determine whether additional genetic factors could contribute to phenotypic variability, Family H and another multigenerational A53T kindred were analyzed for parkin polymorphisms. We identified a previously described variant in parkin exon 4 associated with increased PD risk (S167N). The two A53T heterozygotes had markedly different neuropathology and different parkin genotypes: A N167 homozygote had early onset rapidly progressive disease, early dementia, myoclonus and sleep disorder, while a S167 homozygote had late onset, slowly progressive disease and late dementia. Both had brainstem, cortical, and intraneuritic Lewy bodies (LB). The N167 individual had widespread cortical neurofibrillary degeneration, while the S167 individual had only medial temporal lobe neurofibrillary degeneration. The N167 individual had severe neuronal loss in CA2 associated with Lewy neurites (LN), while the S167 individual had severe neuronal loss in CA1 associated with TDP-43 immunoreactive neuronal inclusions. These findings implicate TDP-43 in the pathology of familial PD and suggest that parkin may act as a modifier of the A53T α-synuclein phenotype of familial PD. Furthermore, they suggest a mechanism by which a rare genetic variant that is associated with a minor increase of PD risk in the heterozygous state may, in the homozygous state, exacerbate a disease phenotype associated with a highly penetrant dominant allele.
AB - Individuals with familial Parkinson's disease (PD) due to a monogenic defect can show considerable clinical and neuropathological variability. To identify factors underlying this variability, histopathological analysis was performed in two clinically different A53T α-synuclein heterozygotes from Family H, a multigenerational α-synuclein A53T kindred. To determine whether additional genetic factors could contribute to phenotypic variability, Family H and another multigenerational A53T kindred were analyzed for parkin polymorphisms. We identified a previously described variant in parkin exon 4 associated with increased PD risk (S167N). The two A53T heterozygotes had markedly different neuropathology and different parkin genotypes: A N167 homozygote had early onset rapidly progressive disease, early dementia, myoclonus and sleep disorder, while a S167 homozygote had late onset, slowly progressive disease and late dementia. Both had brainstem, cortical, and intraneuritic Lewy bodies (LB). The N167 individual had widespread cortical neurofibrillary degeneration, while the S167 individual had only medial temporal lobe neurofibrillary degeneration. The N167 individual had severe neuronal loss in CA2 associated with Lewy neurites (LN), while the S167 individual had severe neuronal loss in CA1 associated with TDP-43 immunoreactive neuronal inclusions. These findings implicate TDP-43 in the pathology of familial PD and suggest that parkin may act as a modifier of the A53T α-synuclein phenotype of familial PD. Furthermore, they suggest a mechanism by which a rare genetic variant that is associated with a minor increase of PD risk in the heterozygous state may, in the homozygous state, exacerbate a disease phenotype associated with a highly penetrant dominant allele.
KW - Familial Parkinson's disease
KW - Genetic polymorphism
KW - Parkin protein
KW - Protein TDP-43
KW - α-Synuclein
UR - http://www.scopus.com/inward/record.url?scp=47749128106&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=47749128106&partnerID=8YFLogxK
U2 - 10.1007/s00401-008-0372-4
DO - 10.1007/s00401-008-0372-4
M3 - Article
C2 - 18389263
AN - SCOPUS:47749128106
SN - 0001-6322
VL - 116
SP - 25
EP - 35
JO - Acta Neuropathologica
JF - Acta Neuropathologica
IS - 1
ER -